Hormonal
GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) induce significant weight loss (≥10%) and reduce major adverse cardiovascular events (MACE) in patients with obesity, outperforming conventional anti-obesity drugs and lifestyle modification alone.
If you have obesity and are at risk for heart disease, GLP-1 receptor agonists like semaglutide or liraglutide are currently the most effective pharmacological options for achieving significant weight loss (often >10%) and reducing cardiovascular risk. Unlike older weight-loss drugs or lifestyle changes alone, these medications address the hormonal drivers of weight regain and offer specific heart benefits. However, they require long-term use to maintain results, and treatment should be discussed with a healthcare provider to weigh benefits against costs and side effects.
GLP-1RAs are potential anti-obesity drugs that satisfy the requirements for ORCVD prevention... semaglutide has the potential to reduce the risk of ORCVDs... tirzepatide therapy is also expected to reduce the risk of ORCVDs.
Why this rating
Based on large-scale clinical trials (SCALE, STEP-1, SURMOUNT-1) and meta-analyses cited, though some long-term CV outcome data is still ongoing.
Source
Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists
Kosuke Sawami et al. · Cardiovascular Diabetology · 2022
DOI 10.1186/s12933-022-01611-8
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →